Skip to main content
Premium Trial:

Request an Annual Quote

UBS Warburg Starts Coverage of Luminex With a Buy

NEW YORK, Dec. 10 - UBS Warburg on Monday began research coverage of Luminex with a "buy" rating and a $21 price target, according to the financial firm.  

 

Citing Luminex's strengths and focus on the diagnostic market, UBS said it expects the company to post revenues of $42.6 million and a loss of 35 cents per share for 2002.

 

Shares of the Austin, Tex.-based bead-array developer climbed 1.39 percent, or 23 cents, to $16.79 in Nasdaq trading early on Monday. The company's 52-week trading range is $11.95 to $36.19.

 

Luminex is known chiefly for its LabMap technology, which beside genomics and proteomics research is used in pharmaceutical drug discovery, clinical diagnostics, and biomedical research.

 

In September, the American Society of Histocompatibility and Immunogenetics cleared Orchid Biosciences to perform human leukocyte antigen testing using the LabMap platform. Orchid becomes the first firm to be certified to perform the testing with the LabMap technology.

The Scan

Removal Inquiry

The Wall Street Journal reports that US lawmakers are seeking additional information about the request to remove SARS-CoV-2 sequence data from a database run by the National Institutes of Health.

Likely to End in Spring

Free lateral flow testing for SARS-CoV-2 may end in the UK by next spring, the head of Innova Medical Group says, according to the Financial Times.

Searching for More Codes

NPR reports that the US Department of Justice has accused an insurance and a data mining company of fraud.

Genome Biology Papers on GWAS Fine-Mapping Method, COVID-19 Susceptibility, Rheumatoid Arthritis

In Genome Biology this week: integrative fine-mapping approach, analysis of locus linked to COVID-19 susceptibility and severity, and more.